Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature

Journal of Clinical Oncology

Volumn 22, Issue 4, 2004, Pages 735-742

  Liede, Alexander ^a   Karlan, Beth Y ^a   Narod, Steven A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLON CANCER; GENE MUTATION; HETEROZYGOTE; HUMAN; MELANOMA; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STOMACH CANCER; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; MALE; MUTATION; NEOPLASM; RISK; TUMOR SUPPRESSOR GENE;

EPIDEMIOLOGY, MOLECULAR; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; NEOPLASMS; RISK;

EID: 1442307845     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.055     Document Type: Review

References (72)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
2. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995
3. Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265:2088-2090, 1994
4. Tonin P, Ghadirian P, Phelan C, et al: A large multisite cancer family is linked to BRCA2. J Med Genet 32:982-984, 1995
5. The U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999 Incidence. Atlanta, GA, Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2002
6. Thompson D, Easton D: Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68:410-419, 2001
7. Lehrer S, Fodor F, Stock RG, et al: Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 78:771-773, 1998
8. Nastiuk KL, Mansukhani M, Terry MB, et al: Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 40:172-177, 1999
9. Hubert A, Peretz T, Manor O, et al: The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921-924, 1999
10. Vazina A, Baniel J, Yaacobi Y, et al: The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 83:463-466, 2000
11. Struewing JP, Coriaty ZM, Ron E, et al: Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 65:1800-1802, 1999
12. Sverdlov RS, Barshack I, Bar Sade RB, et al: Genetic analyses of male breast cancer in Israel. Genet Test 4:313-317, 2000
13. Frank TS, Deffenbaugh AM, Reid JE, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J Clin Oncol 20:1480-1490, 2002
14. Chen-Shtoyerman R, Figer A, Fidder HH, et al: The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. Br J Cancer 84:475-477, 2001
15. Ozcelik H, Schmocker B, Di Nicola N, et al: Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16:17-18, 1997
16. Iscovich J, Abdulrazik M, Cour C, et al: Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. Int J Cancer 98:42-44, 2002
17. Johannesdottir G, Gudmundsson J, Bergthorsson JT, et al: High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 56:3663-3665, 1996
18. Sigurdsson S, Thorlacius S, Tomasson J, et al: BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75:758-761, 1997
19. Edwards SM, Kote-Jarai Z, Meitz J, et al: Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1-12, 2003
20. Couch FJ, Farid LM, DeShano ML, et al: BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13:123-125, 1996
21. Friedman LS, Gayther SA, Kurosaki T, et al: Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313-319, 1997
22. Mavraki E, Gray IC, Bishop DT, et al: Germline BRCA2 mutations in men with breast cancer. Br J Cancer 76:1428-1431, 1997
23. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al: Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60:1079-1084, 1997
24. Thorlacius S, Struewing JP, Hartge P, et al: Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337-1339, 1998
25. Haraldsson K, Loman N, Zhang QX, et al: BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58:1367-1371, 1998
26. Kwiatkowska E, Teresiak M, Lamperska KM, et al: BRCA2 germline mutations in male breast cancer patients in the Polish population. Hum Mutat 17:73, 2001
27. Basham VM, Lipscombe JM, Ward JM, et al: BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4:R2, 2002
28. Ottini L, Masala G, D'Amico C, et al: BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: A population-based study in Italy. Cancer Res 63:342-347, 2003
29. Goggins M, Schutte M, Lu J, et al: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360-5364, 1996
30. Lal G, Liu G, Schmocker B, et al: Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60:409-416, 2000
31. Real FX, Malats N, Lesca G, et al: Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut 50: 653-657, 2002
32. Sinilnikova OM, Egan KM, Quinn JL, et al: Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer 82:325-328, 1999
33. Scott RJ, Vajdic CM, Armstrong BK, et al: BRCA2 mutations in a population-based series of patients with ocular melanoma. Int J Cancer 102:188-191, 2002
34. Hearle N, Damato BE, Humphreys J, et al: Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci 44:458-462, 2003
35. Csokay B, Udvarhelyi N, Sulyok Z, et al: High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59:995-998, 1999
36. Easton DF, Steele L, Fields P, et al: Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61:120-128, 1997
37. SEER Database: Surveillance, Epidemiology, and End Results (SEER), 2003. http://seer.cancer.gov/
38. Struewing JP, Brody LC, Erdos MR, et al: Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. Am J Hum Genet 57:1-7, 1995
39. Struewing JP, Abeliovich D, Peretz T, et al: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 11:198-200, 1995
40. Thompson D, Easton D: Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329-336, 2002
41. Brose MS, Rebbeck TR, Calzone KA, et al: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365-1372, 2002
42. Thompson D, Easton DF: Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365, 2002
43. Struewing JP, Hange P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
44. The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310-1316, 1999
45. Moslehi R, Chu W, Karlan B, et al: BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259-1272, 2000
46. Wilkens EP, Freije D, Xu J, et al: No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 39:280-284, 1999
47. Sinclair CS, Berry R, Schaid D, et al: BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 60:1371-1375, 2000
48. Gayther SA, de Foy KA, Harrington P, et al: The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer: The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 60:4513-4518. 2000
49. Tulinius H, Olafsdottir GH, Sigvaldason H, et al: The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 39:457-462, 2002
50. Gayther SA, Mangion J, Russell P, et al: Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15:103-105, 1997
51. Bignell G, Micklem G, Stratton MR, et al: The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet 6:53-58, 1997
52. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1 mutation carriers: Breast Cancer Linkage Consortium. Lancet 343:692-695, 1994
53. Peelen T, de Leeuw W, van Lent K, et al: Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis. Int J Cancer 88:778-782, 2000
54. Roa BB, Boyd AA, Volcik K, et al: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet 14:185-187, 1996
55. Fodor FH, Weston A, Bleiweiss IJ, et al: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63:45-51, 1998
56. Phelan CM, Lancaster JM, Tonin P, et al: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 13:120-122, 1996
57. [erratum in Nat Genet 13: 374, 1996]
58. Tonin P, Weber B, Offit K, et al: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature Med 2:1179-1183, 1996
59. Hahn SA, Greenhalf B, Ellis I, et al: BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214-221, 2003
60. Murphy KM, Brune KA, Griffin C, et al: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 62:3789-3793, 2002
61. Berman DB, Costalas J, Schultz DC, et al: A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 56:3409-3414, 1996
62. Jakubowska A, Nej K, Huzarski T, et al: BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 87:888-891, 2002
63. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2-Cancer Genetics Studies Consortium. JAMA 277:997-1003, 1997
64. Winawer S, Fletcher R, Rex D, et al: Colerectal cancer screening and surveillance: Clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124:544-560, 2003
65. Liede A, Malik IA, Aziz Z, et al: Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 71:595-606, 2002
66. Risch HA, McLaughlin JR, Cole DEC, et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700-710, 2001
67. Oddoux C, Struewing JP, Clayton CM. et al: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188-190, 1996
68. Liede A, Metcalfe K, Hanna D, et al: Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 67:494-504, 2000
69. Daly PA, Nolan C, Green A, et al: Predictive testing for BRCA1 and 2 mutations: A male contribution. Ann Oncol 14:549-553, 2003
70. Lodder L, Frets PG, Trijsburg RW, et al: Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: An exploration of attitudes and psychological functioning during genetic testing. Eur J Hum Genet 9:492-500, 2001
71. Dorval M, Patenaude AF, Schneider KA, et al: Anticipated versus actual emotional reactions to disclosure of results of genetic tests for cancer susceptibility: Findings from p53 and BRCA1 testing programs. J Clin Oncol 18:2135-2142, 2000
72. Breslow NE, Day NE: The design and analysis of cohort studies, in Davis W (ed): Statistical Methods in Cancer Research (vol II). Lyon, France, International Agency for Research on Cancer, 1987